Johns Hopkins

 

Insights from 2023 ASH Annual Meeting
A

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or Venetoclax in Newly Diagnosed Patients With IDH1mut AML - A RWE Study"

By Insights from 2023 ASH Annual Meeting FEATURING Alexander Ambinder
By Insights from 2023 ASH Annual Meeting FEATURING Alexander Ambinder
38 views
December 19, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

10:25
Exelixis

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser
Videos
08:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosiden…

Feat. A. Ambinder
13:15
Johns Hopkins

Output From the National MDS Study: Utility of Targeted Gene Sequenc…

Feat. A. DeZern
16:27
Johns Hopkins

Targeting BRAF-Altered Glioma in Adults

Feat. K. Schreck
15:49
Johns Hopkins

Severe Aplastic Anemia: What's on the Horizon?

Feat. A. DeZern
09:23
Johns Hopkins

Advancements in Systemic Therapy for Advanced HCC: Where Are We Going

Feat. M. Yarchoan
34:01
MedNews Week

Latest Treatment Strategies and Standard of Care for Pancreatic Canc…

Feat. M. Pishvaian
21:21
Johns Hopkins

KRASG12C Mutation in NSCLC: Current Data and Future Directions

Feat. S. Rosner